Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of AK3280 in idiopathic pulmonary fibrosis
CTR20221183Phase 2Completed
- Sponsor
- Ark Biosciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AK3280 in idiopathic pulmonary fibrosis (IPF), sponsored by Ark Biosciences. Started Aug 2022; status: completed.
02
Drugs
AK3280
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20221183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221183.